HUTCHMED (00013.HK): Two of Three Drugs Add NRDL Indications
NewTimeSpace News: On 16 November 2026, HUTCHMED (China) Limited (stock code: 00013) announced that, following its contract renewal with China's National Healthcare Security Administration, ELUNATE® (fruquintinib), ORPATHYS® (savolitinib) and SULANDA® (surufatinib) will remain on the updated National Reimbursement Drug List (NRDL) effective 1 January 2027.
ELUNATE® is newly included, in combination with sintilimab injection, for patients with locally advanced or metastatic renal cell carcinoma who have failed prior VEGFR tyrosine kinase inhibitor therapy and have not received PD-1 or PD-L1 inhibitor therapy in the first-line setting.
ORPATHYS® is newly included, in combination with osimertinib, for patients with locally advanced or metastatic EGFR mutation-positive non-squamous non-small cell lung cancer with MET amplification after progression on EGFR-TKI therapy, and its indication for MET exon 14 skipping alteration is also renewed. The NRDL maintains coverage for all other previously included indications of the three drugs under their current multi-year agreements.
- SIHUAN PHARM (00460.HK): bireociclib indication added to national NRDL
- HUTCHMED (00013.HK): Sovleplenib Wins FDA Orphan Drug Status for AIHA
- HUTCHMED (00013.HK): savolitinib+osimertinib filings accepted in Europe, Japan
- HUTCHMED (00013.HK): Sovleplenib Wins FDA Orphan Drug Status for Primary ITP
- HUTCHMED (00013.HK): Expert Briefing on Savolitinib Set for 5 November